Literature DB >> 334800

Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.

J B Pennebaker, J N Gilliam, M Ziff.   

Abstract

36 systemic lupus erythematosus patients with native DNA binding activity (nDNA-BA) in the serum and subepidermal immunoglobulin deposits were studied to determine the relationship of the immunoglobulin (Ig) class distribution of serum nDNA-BA to the clinical characteristics of their disease and to the Ig class present at the dermal-epidermal junction (DEJ). The patients with predominantly (86-98%) IgM nDNA-BA in the serum had less active disease, mild or no renal involvement, and longer survival than those with predominantly (51-95%) IgG nDNA-BA in the serum. Renal biopsies in eight patients with predominantly IgM nDNA-BA in the serum showed relatively benign histologic changes in the kidney. In contrast, renal tissue from 23 patients with predominantly IgG nDNA-BA showed more severe histologic changes. All patients had multiple skin biopsies. Patients with predominantly IgM nDNA-BA consistently had only IgM at the DEJ. Patients with predominantly IgG nDNA-BA had IgG, usually in association with IgM, at the DEJ. The findings demonstrate that a minority of systemic lupus erythematosus patients may exhibit a limited anti-nDNA response characterized by the presence of chiefly IgM nDNA-BA in the serum and that this is reflected by the presence of mild disease and IgM alone at the DEJ. The development of IgG nDNA-BA is associated with more severe and active disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334800      PMCID: PMC372489          DOI: 10.1172/JCI108892

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  A Millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus.

Authors:  B Ginsberg; H Keiser
Journal:  Arthritis Rheum       Date:  1973 Mar-Apr

2.  Anti-DNA antibodies and renal lesions of patients with systemic lupus erythematosus.

Authors:  D Koffler; V Agnello; R I Carr; H G Kunkel
Journal:  Transplant Proc       Date:  1969-12       Impact factor: 1.066

3.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

4.  Purification and further properties of single-strand-specific nuclease from Aspergillus oryzae.

Authors:  V M Vogt
Journal:  Eur J Biochem       Date:  1973-02-15

5.  The heterogeneity of antibody affinity in inbred mice and its possible immunopathologic significance.

Authors:  R E Petty; M W Steward; J F Soothill
Journal:  Clin Exp Immunol       Date:  1972-10       Impact factor: 4.330

6.  IgM and IgG antibodies to DNA, RNA, and DNA:RNA in systemic lupus erythematosus.

Authors:  N Talal; R Pillarisetty
Journal:  Clin Immunol Immunopathol       Date:  1975-05

7.  The occurrence and nature of precipitating antibodies in anti-DNA sera.

Authors:  C Dorsch; E V Barnett
Journal:  Clin Immunol Immunopathol       Date:  1974-04

8.  Specificities of antibodies to native DNA.

Authors:  J J Picazo; E M Tan
Journal:  Scand J Rheumatol Suppl       Date:  1975

9.  Immunoglobulin G subclass of human antinuclear antibodies.

Authors:  T Tojo; G J Friou; H L Spiegelberg
Journal:  Clin Exp Immunol       Date:  1970-01       Impact factor: 4.330

10.  Immunoglobulin in clinically uninvolved skin in systemic lupus erythematosus: association with renal disease.

Authors:  J N Gilliam; D E Cheatum; E R Hurd; P Stastny; M Ziff
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  16 in total

1.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

Review 2.  Factors influencing immune complex localisation.

Authors:  L Schrieber; R Penny
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

3.  Complement, lymphocytotoxins and immune complexes in infectious mononucleosis: serial studies in uncomplicated cases.

Authors:  J A Charlesworth; J W Quin; G J Macdonald; R J Lennane; C R Boughton
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

4.  Evaluation of an ELISA system for determination of class-specific antibodies to native and denatured DNA in man.

Authors:  G M Halliday; M R Salaman; M H Seifert; K J Johnson; A D Malcolm
Journal:  Ann Rheum Dis       Date:  1985-08       Impact factor: 19.103

5.  Immunoglobulin classes in skin basement membrane in systemic lupus erythematosus: clinical significance and comparison with classes of serum anti-DNA antibodies.

Authors:  B Bresnihan; G M Hale; C C Bunn; G R Hughes
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

Review 6.  Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE).

Authors:  T Swaak; R Smeenk
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

7.  Chronic active hepatitis with high level of anti-ds-DNA detected by a solid phase radioimmunoassay.

Authors:  A Peretz; F Mascart-Lemone; G Nuttin; J P Famaey
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

8.  Circulating DNA-antibodies in systemic lupus erythematosus.

Authors:  T Helve; A M Teppo; P Kurki; O Wegelius
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

9.  Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen.

Authors:  M Shiraki; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  A new assay for anti-DNA antibodies in serum which includes the measurement of anti-Z-DNA.

Authors:  P D Van Helden; L Van Lill; A J Bester; L De Waal; E G Hoal-van Helden
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.